Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions

European Journal of Pharmaceutical Sciences

Volumn 28, Issue 3, 2006, Pages 189-195

  Piette, Marie ^a   Evrard, Brigitte ^a   Frankenne, Francis ^a   Chiap, Patrice ^a   Bertholet, Pascal ^a   Castagne, Delphine ^a   Foidart, Jean Michel ^a   Delattre, Luc ^a   Piel, Géraldine ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Bioavailability; Cyclodextrin; Matrix metalloproteinase inhibitor; Ro 28 2653; Ternary inclusion complexes

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; 5 BIPHENYL 4 YL 5 [4 (4 NITROPHENYL)PIPERAZIN 1 YL]PYRIMIDINE 2,4,6 TRIONE; CYCLODEXTRIN; LYSINE; MATRIX METALLOPROTEINASE INHIBITOR; RO 28 2653; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENTIATION; DRUG SOLUBILITY; FEMALE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; INJECTIONS, INTRAVENOUS; LYSINE; MATRIX METALLOPROTEINASES; PIPERAZINES; PROTEASE INHIBITORS; PYRIMIDINES; SHEEP; SOLUBILITY; SOLUTIONS; SUSPENSIONS;

EID: 33646812941     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.01.011     Document Type: Article

References (37)

1. Arlt M., Kopitz C., Pennington C., Watson K.L., Krell H.W., Bode W., Gansbacher B., Khokha R., Edwards D.R., and Kruger A. Increase in gelatinase-specificity of matrix metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. 62 19 (2002) 5543-5550
2. 1H NMR spectroscopy and molecular modeling studies, preparation and stability study of nebulizable solutions. J. Pharm. Pharm. Sci. 8 2 (2005) 164-175. http://www.cspscanada.org
3. Boroujerdi M. Pharmacokinetics, Principles and Applications (2002), McGraw-Hill Companies, New York
4. Brewster M.E., and Loftsson T. The use of chemically modified cyclodextrins in the development of formulations for chemical delivery systems. Pharmazie 57 2 (2002) 94-101
5. Chiap P., Piette M., Evrard B., Frankenne F., Christiaens B., Piel G., Cataldo D., Foidart J.M., Delattre L., Crommen J., and Hubert P. Automated method for the determination of a new matrix metalloproteinase inhibitor in ovine plasma and serum by coupling of restricted access material for on-line sample clean-up to liquid chromatography. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 817 1 (2005) 109-117
6. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2 3 (2002) 161-174
7. Fingleton B. Matrix metalloproteinase inhibitors for cancer therapy: the current situation and future prospects. Expert Opin. Ther. Targets 7 3 (2003) 385-397
8. Frijlink H.W., Eissens A.C., Schoonen A.J.M., and Lerk C.F. The effects of cyclodextrins on drug absorption. II. In vivo observations. Int. J. Pharm. 64 2-3 (1990) 195-205
9. Grams F., Brandstetter H., D'Alo S., Geppert D., Krell H.W., Leinert H., Livi V., Menta E., Oliva A., and Zimmermann G. Pyrimidine-2,4,6-triones: a new effective and selective class of matrix metalloproteinase inhibitors. Biol. Chem. 382 8 (2001) 1277-1285
10. Higuchi T., and Connors K.A. Phase solubility techniques. Adv. Anal. Chem. Instrum. 4 (1965) 117-212
11. Hubert P., Ceccato A., Chiap P., Toussaint B., and Crommen J. Préparation des échantillons d'origine biologique préalable à leur analyse chromatographique. STP Pharma Pratiques 9 2 (1999) 160-180
12. Hubert P., Chiap P., Crommen J., Boulanger B., Chapuzet E., Mercier N., Bervoas-Martin S., Chevalier P., Grandjean D., Lagorce P., Lallier M., Laparra M.C., Laurentie M., and Nivet J.C. The SFSTP guide on the validation of chromatographic methods for drug bioanalysis: from the Washington Conference to the laboratory. Anal. Chim. Acta 391 2 (1999) 135-148
13. Hubert P., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewe W., Feinberg M., Lallier M., Laurentie M., Mercier N., Nivet C., Muzard G., and Valat L. Validation des procédures analytiques quantitatives, Harmonisation des démarches. STP Pharma Pratiques 13 (2003) 27-64
14. Hubert P., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewe W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., and Valat L. Harmonization of strategies for the validation of quantitative analytical procedures: a SFSTP proposal-part I. J. Pharm. Biomed. Anal. 36 3 (2004) 579-586
15. Irie T., and Uekama K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86 2 (1997) 147-162
16. Itoh T., Tanioka M., Yoshida H., Yoshioka T., Nishimoto H., and Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res. 58 5 (1998) 1048-1051
17. Itoh T., Tanioka M., Matsuda H., Nishimoto H., Yoshioka T., Suzuki R., and Uehira M. Experimental metastasis is suppressed in MMP-9-deficient mice. Clin. Exp. Metastas. 17 2 (1999) 177-181
18. Lein M., Jung K., Ortel B., Stephan C., Rothaug W., Juchem R., Johannsen M., Deger S., Schnorr D., Loening S., and Krell H.W. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model. Oncogene 21 13 (2002) 2089-2096
19. Loftsson T., and Brewster M.E. Pharmaceutical applications of cyclodextrins. I. Drug solubilization and stabilization. J. Pharm. Sci. 85 10 (1996) 1017-1025
20. Ma D.Q., Rajewski R.A., and Stella V.J. New injectable melphalan formulations utilizing (SBE)(7m)-beta-CD or HP-beta-CD. Int. J. Pharm. 189 2 (1999) 227-234
21. Mangoldt D., Sinn B., Lein M., Krell H.W., Schnorr D., Loening S.A., and Jung K. The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells. Apoptosis 7 3 (2002) 217-220
22. Mosher G., and Thompson D.O. Complexation and cyclodextrins. In: Swarbrick J., and Boylan J.C. (Eds). Encyclopaedia of Pharmaceutical Technology (2000), Marcel Dekker, New York 49-88
23. Mura P., Maestrelli F., and Cirri M. Ternary systems of naproxen with hydroxypropyl-[beta]-cyclodextrin and aminoacids. Int. J. Pharm. 260 2 (2003) 293-302
24. Noel A., Maquoi E., Devy L., Olivier F., Roland G., Tiefenhaler G., Krell H.W., and Foidart J.M. Antitumor and antiangiogenic activities of Ro 28-2653, a synthetic matrix metalloproteinase inhibitor. Clin. Cancer Res. 6 (2000) 4524
25. Noel A., Maillard C., Rocks N., Jost M., Chabottaux V., Sounni N.E., Maquoi E., Cataldo D., and Foidart J.M. Membrane associated proteases and their inhibitors in tumour angiogenesis. J. Clin. Pathol. 57 6 (2004) 577-584
26. Opalka J.R., Gellerich F.N., Kling L., Muller-Beckmann B., and Zierz S. Effect of the new matrix metalloproteinase inhibitor Ro-28-2653 on mitochondrial function. Biochem. Pharmacol. 63 4 (2002) 725-732
27. Overall C.M., and Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer 2 9 (2002) 657-672
28. Piel G., Pirotte B., Delneuville I., Neven P., Llabres G., Delarge J., and Delattre L. Study of the influence of both cyclodextrins and l-lysine on the aqueous solubility of nimesulide; isolation and characterization of nimesulide-l-lysine-cyclodextrin complexes. J. Pharm. Sci. 86 4 (1997) 475-480
29. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. II. In vivo drug delivery. J. Pharm. Sci. 85 11 (1996) 1142-1169
30. Redenti E., Szente L., and Szejtli J. Drug/cyclodextrin/hydroxy acid multicomponent systems. Properties and pharmaceutical applications. J. Pharm. Sci. 89 1 (2000) 1-8
31. Redenti E., Szente L., and Szejtli J. Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. J. Pharm. Sci. 90 8 (2001) 979-986
32. Sounni N.E., Janssen M., Foidart J.M., and Noel A. Membrane type-1 matrix metalloproteinase and TIMP-2 in tumor angiogenesis. Matrix Biol. 22 1 (2003) 55-61
33. Souverain S., Rudaz S., and Veuthey J.L. Restricted access materials and large particle supports for on-line sample preparation: an attractive approach for biological fluids analysis. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 801 2 (2004) 141-156
34. Talvensaari-Mattila A., Paakko P., Hoyhtya M., Blanco-Sequeiros G., and Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. Cancer 83 6 (1998) 1153-1162
35. Taraboletti G., and Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. 1 4 (2001) 378-384
36. Vihinen P., and Kahari V.M. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer 99 2 (2002) 157-166
37. Yu Z., and Westerlund D. Influence of mobile phase conditions on the clean-up effect of restricted-access media precolumns for plasma samples injected in a column-switching system. Chromatographia 44 11-12 (1997) 589-594